412 related articles for article (PubMed ID: 30925904)
1. The prognostic value of PKM2 and its correlation with tumour cell PD-L1 in lung adenocarcinoma.
Guo CY; Zhu Q; Tou FF; Wen XM; Kuang YK; Hu H
BMC Cancer; 2019 Mar; 19(1):289. PubMed ID: 30925904
[TBL] [Abstract][Full Text] [Related]
2. Association of PD-L1 expression and PD-L1 gene polymorphism with poor prognosis in lung adenocarcinoma and squamous cell carcinoma.
Yeo MK; Choi SY; Seong IO; Suh KS; Kim JM; Kim KH
Hum Pathol; 2017 Oct; 68():103-111. PubMed ID: 28851662
[TBL] [Abstract][Full Text] [Related]
3. Programmed Death Cell Ligand 1 (PD-L1) Is Associated With Survival in Stage I Non-Small Cell Lung Cancer.
Sepesi B; Cuentas EP; Canales JR; Behrens C; Correa AM; Vaporciyan A; Weissferdt A; Kalhor N; Moran C; Swisher S; Wistuba I
Semin Thorac Cardiovasc Surg; 2017 Autumn; 29(3):408-415. PubMed ID: 29195578
[TBL] [Abstract][Full Text] [Related]
4. The transcription factor TEAD4 enhances lung adenocarcinoma progression through enhancing PKM2 mediated glycolysis.
Hu Y; Mu H; Deng Z
Cell Biol Int; 2021 Oct; 45(10):2063-2073. PubMed ID: 34196069
[TBL] [Abstract][Full Text] [Related]
5. Programmed death-ligand 1 expression associated with molecular characteristics in surgically resected lung adenocarcinoma.
Song Z; Yu X; Cheng G; Zhang Y
J Transl Med; 2016 Jun; 14(1):188. PubMed ID: 27342566
[TBL] [Abstract][Full Text] [Related]
6. Both high expression of pyruvate kinase M2 and vascular endothelial growth factor-C predicts poorer prognosis in human breast cancer.
Lin Y; Liu F; Fan Y; Qian X; Lang R; Gu F; Gu J; Fu L
Int J Clin Exp Pathol; 2015; 8(7):8028-37. PubMed ID: 26339369
[TBL] [Abstract][Full Text] [Related]
7. FAM83A drives PD-L1 expression via ERK signaling and FAM83A/PD-L1 co-expression correlates with poor prognosis in lung adenocarcinoma.
Zhou F; Wang X; Liu F; Meng Q; Yu Y
Int J Clin Oncol; 2020 Sep; 25(9):1612-1623. PubMed ID: 32430734
[TBL] [Abstract][Full Text] [Related]
8. Knockdown of PKM2 Suppresses Tumor Growth and Invasion in Lung Adenocarcinoma.
Sun H; Zhu A; Zhang L; Zhang J; Zhong Z; Wang F
Int J Mol Sci; 2015 Oct; 16(10):24574-87. PubMed ID: 26501265
[TBL] [Abstract][Full Text] [Related]
9. Gene landscape and correlation between B-cell infiltration and programmed death ligand 1 expression in lung adenocarcinoma patients from The Cancer Genome Atlas data set.
Ho KH; Chang CJ; Huang TW; Shih CM; Liu AJ; Chen PH; Cheng KT; Chen KC
PLoS One; 2018; 13(12):e0208459. PubMed ID: 30521597
[TBL] [Abstract][Full Text] [Related]
10. Prediction of Responsiveness to PD-L1/PD-1 Inhibitors Using miRNA Profiles Associated With PD-L1 Expression in Lung Adenocarcinoma and Squamous Cell Carcinoma.
Koh YW; Han JH; Haam S; Lee HW
Anticancer Res; 2024 May; 44(5):2081-2089. PubMed ID: 38677736
[TBL] [Abstract][Full Text] [Related]
11. SAM68 promotes tumorigenesis in lung adenocarcinoma by regulating metabolic conversion via PKM alternative splicing.
Zhu S; Chen W; Wang J; Qi L; Pan H; Feng Z; Tian D
Theranostics; 2021; 11(7):3359-3375. PubMed ID: 33537092
[No Abstract] [Full Text] [Related]
12. Aberrant S100A16 expression might be an independent prognostic indicator of unfavorable survival in non-small cell lung adenocarcinoma.
Chen D; Luo L; Liang C
PLoS One; 2018; 13(5):e0197402. PubMed ID: 29746588
[TBL] [Abstract][Full Text] [Related]
13. Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer.
Li Y; Liang L; Dai W; Cai G; Xu Y; Li X; Li Q; Cai S
Mol Cancer; 2016 Aug; 15(1):55. PubMed ID: 27552968
[TBL] [Abstract][Full Text] [Related]
14. SLC7A11 inhibits ferroptosis and downregulates PD-L1 levels in lung adenocarcinoma.
Huang Z; Chen X; Wang Y; Yuan J; Li J; Hang W; Meng H
Front Immunol; 2024; 15():1372215. PubMed ID: 38655266
[TBL] [Abstract][Full Text] [Related]
15. Comparative proteomic approach identifies PKM2 and cofilin-1 as potential diagnostic, prognostic and therapeutic targets for pulmonary adenocarcinoma.
Peng XC; Gong FM; Zhao YW; Zhou LX; Xie YW; Liao HL; Lin HJ; Li ZY; Tang MH; Tong AP
PLoS One; 2011; 6(11):e27309. PubMed ID: 22087286
[TBL] [Abstract][Full Text] [Related]
16. Favorable outcome of patients with lung adenocarcinoma harboring POLE mutations and expressing high PD-L1.
Liu L; Ruiz J; O'Neill SS; Grant SC; Petty WJ; Yang M; Chen K; Topaloglu U; Pasche B; Zhang W
Mol Cancer; 2018 Apr; 17(1):81. PubMed ID: 29650000
[TBL] [Abstract][Full Text] [Related]
17. Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1).
Shimoji M; Shimizu S; Sato K; Suda K; Kobayashi Y; Tomizawa K; Takemoto T; Mitsudomi T
Lung Cancer; 2016 Aug; 98():69-75. PubMed ID: 27393509
[TBL] [Abstract][Full Text] [Related]
18. PD-L1 mRNA expression in EGFR-mutant lung adenocarcinoma.
Isobe K; Kakimoto A; Mikami T; Kaburaki K; Kobayashi H; Yoshizawa T; Nakano Y; Makino T; Otsuka H; Sano G; Sugino K; Sakamoto S; Takai Y; Tochigi N; Iyoda A; Homma S
Oncol Rep; 2018 Jul; 40(1):331-338. PubMed ID: 29767258
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1), CD8+ Tumor-Infiltrating Lymphocytes and p53 in Non-Small Cell Lung Cancer: An Immunohistochemical Study.
Rashed HE; Abdelrahman AE; Abdelgawad M; Balata S; Shabrawy ME
Turk Patoloji Derg; 2017; 1(1):211-222. PubMed ID: 28832075
[TBL] [Abstract][Full Text] [Related]
20. High expression of programmed cell death 1 ligand 1 in lung adenocarcinoma is a poor prognostic factor particularly in smokers and wild-type epidermal growth-factor receptor cases.
Mori S; Motoi N; Ninomiya H; Matsuura Y; Nakao M; Mun M; Okumura S; Nishio M; Morikawa T; Ishikawa Y
Pathol Int; 2017 Jan; 67(1):37-44. PubMed ID: 27976463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]